"Calibre Phase 2 Reverse-Circulation drilling programme significantly expands the deposit size:
This is great news. While assay results may take approximately six weeks, the company could release interim results at any time.
- extends strike length of overall Calibre gold-copper mineralisation to in excess of 1.5km and up to 480m across strike and remains open in most directions.
- extends strike length of Calibre North gold-copper mineralisation which includes zones of possible higher grade gold (with copper) mineralisation, by a further 300 to 400m north to in excess of 700m in total strike length;
- strike extent of Calibre North mineralisation commensurate with previously reported Exploration Target; and
- mineralisation open down dip, across width and along strike to the south and possibly the north."
No drilling for Stage 3 yet while they undertake geophysical surveying to identify possible drill targets.
- Forums
- ASX - By Stock
- Ann: Calibre 2015 Phase 2 RC Drilling Update No. 3
"Calibre Phase 2 Reverse-Circulation drilling programme...
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AZY (ASX) to my watchlist
|
|||||
Last
1.1¢ |
Change
-0.001(8.33%) |
Mkt cap ! $51.81M |
Open | High | Low | Value | Volume |
1.2¢ | 1.2¢ | 1.1¢ | $87.49K | 7.534M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
36 | 20884956 | 1.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 11814202 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
36 | 20884956 | 0.011 |
54 | 20852853 | 0.010 |
33 | 13809155 | 0.009 |
18 | 8352820 | 0.008 |
4 | 2250000 | 0.007 |
Price($) | Vol. | No. |
---|---|---|
0.012 | 11814202 | 13 |
0.013 | 11067216 | 8 |
0.014 | 7141789 | 10 |
0.015 | 4568929 | 9 |
0.016 | 4415631 | 10 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
AZY (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online